Abacavir and Lamivudine
Brand Names: Abacavir and Lamivudine Generic
Methodology & AI Transparency ⓘ
Abacavir and Lamivudine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 75% satisfaction benchmark (RxCUI 602393).
- 3 Typical cash cost range: Public pharmacy ledger: $59.61 low cash benchmark vs. $146.04 chain retail average ($1.2621/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Abacavir and Lamivudine tolerability events: nausea (12.4%), headache (11%), dizziness (6.7%).
Ask our AI Specialists anything about Abacavir and Lamivudine
Abacavir and Lamivudine Mechanism, CYP450 Pathways & DailyMed Monograph
Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Abacavir and lamivudine tablets, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1)
12.1 Mechanism of Action Abacavir and lamivudine is an antiretroviral agent with activity against HIV-1 . In clinical regimens (600 mg/1 / 300 mg/1 Tablet, Film Coated, Longitudinal Abacavir and Lamivudine dosing interval tailored to tolerability), Abacavir and Lamivudine executes hepatitis b virus nucleoside analog reverse transcriptase inhibitor target modulation documented under federal RxCUI 602393 and DailyMed 2024-05-19 labeling.
Pharmacokinetic profiling of Abacavir and Lamivudine demonstrates an elimination half-life of Terminal t½ estimated at 10–22 hrs depending on renal/hepatic reserve (Abacavir and Lamivudine) with F ≈ 67%–79% systemic availability after standard oral Abacavir and Lamivudine administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across abacavir and lamivudine regimens, reaching clinical onset within time to peak concentration spans 1 to 3 hrs under abacavir and lamivudine maintenance.
Titration schedules for Abacavir and Lamivudine (600 mg/1 / 300 mg/1 Tablet, Film Coated → Longitudinal Abacavir and Lamivudine dosing interval tailored to tolerability) require excluding abacavir and lamivudine tablets are contraindicated in patients:; who have the hla-b*5701 allele .; with prior hypersensitivity reaction to abacavir or lamivudine.; real-world patient logs highlight nausea (12.4% of reports), headache (11% of reports), diarrhea (9.7% of reports) alongside a 75.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Abacavir and Lamivudine (hepatitis b virus nucleoside analog reverse transcriptase inhibitor).
Botanical enzyme modulators may alter oral first-pass exposure of Abacavir and Lamivudine; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Abacavir and lamivudine tablets are contraindicated in patients:
- who have the HLA-B*5701 allele .
- with prior hypersensitivity reaction to abacavir or lamivudine.
Logged Side-Effect Incidence (21 Reports)
Abacavir and Lamivudine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Abacavir and Lamivudine)
Human clinical trial evidence for Abacavir and Lamivudine is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Abacavir and Lamivudine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.2621/unit (~$37.86/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $146.04 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $59.61 / mo | View logs ↓ |
Abacavir and Lamivudine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Abacavir and Lamivudine RxNorm Concept ID | 602393 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.2621 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $146.04 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $59.61 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Abacavir and Lamivudine Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Abacavir and Lamivudine integrating DailyMed SPL (2024-05-19), CMS NADAC ($1.2621/unit), and 21 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Abacavir and Lamivudine community threads and patient logs by age, biological sex, dosage, and treatment duration.